Florence Fauvelle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Florence Fauvelle has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Emmanuel Luc Barbier
Grenoble Institute Neurosciences, University Grenoble Alpes, INSERM U1216; Grenoble, France
7 shared publications Jean-Claude Debouzy
IRBA, Unité des Rayonnements Non Ionisants et de Biophysique, BP 73, 91220 Brétigny sur Orge, France
5 shared publications- Abdul-Rahman Allouche
Université Claude Bernard Lyon 1
4 shared publications J.C. Debouzy
CRSSA
4 shared publicationsA. Gadelle
CEA-Grenoble, DRF/MC/SCIB/RI2M
3 shared publications- Danielle Graveron-Demilly
Laboratoire CREATIS, CNRS UMR 5220, Inserm U1044, Université Claude Bernard LYON 1, 3 Rue Victor Grignard, CPE, 69616, Villeurbanne, France,
3 shared publications
Latest Publications
- Open Access
Toward clinical implementation of a metabolic blood biomarker for Parkinson’s disease differential diagnosis
: Parkinson’s disease (PD) diagnosis remains delayed and suboptimally accurate, largely due to clinical overlap with atypical parkinsonian syndromes and the lack of reliable biomarkers. In this context, we recently patented a 6-metabolites blood biomarker (6M-BB) for PD diagnosis versus healthy controls (HC), using high field nuclear magnetic resonance (NMR). Here, we evaluated its performance for the differential diagnosis of PD and its translation to clinical In-Vitro Diagnosis (IVDr) NMR platform. Patient serum samples from de novo PD (n=30), multiple system atrophy (MSA, n=30), progressive supranuclear palsy (PSP, n=30), Alzheimer’s disease (AD, n=33), and healthy individuals (n=29), were profiled by proton NMR both at 950 MHz and on an IVDr 600 MHz system. First, we reproduced the 6M-BB performance for PD vs. HC with 87.9% accuracy, but above all, we obtained an overall accuracy of 82.6% across all groups including MSA/PSP. Secondly, the 6M-BB refit using IVDr data achieved an overall accuracy of 77%. Adding VLDL-5 free cholesterol (V5FC) and citrate markedly increased accuracy to 95% for PD vs. HC and 85% vs. MSA/PSP. To conclude, in addition to independently validate the 6M-BB with a new PD/HC cohort, we demonstrated here its ability to efficiently distinguish PD from other confounding parkinsonian syndromes at de novo stage, thereby addressing a major challenge in the early clinical diagnosis of the disease. Its successful transfer to a fully automated, standardized IVDr system, with gains from V5FC and citrate, supports the feasibility and promising potential for clinical implementation, justifying future prospective multicenter studies. One Sentence Summary: We offer a clinically deployable blood biomarker that addresses the major challenge of distinguishing Parkinson’s disease from other parkinsonism.
Open AccessToward clinical implementation of a metabolic blood biomarker for Parkinson’s disease differential diagnosis
: Parkinson’s disease (PD) diagnosis remains delayed and suboptimally accurate, largely due to clinical overlap with atypical parkinsonian syndromes and the lack of reliable biomarkers. In this context, we recently patented a 6-metabolites blood biomarker (6M-BB) for PD diagnosis versus healthy controls (HC), using high field nuclear magnetic resonance (NMR). Here, we evaluated its performance for the differential diagnosis of PD and its translation to clinical In-Vitro Diagnosis (IVDr) NMR platform. Patient serum samples from de novo PD (n=30), multiple system atrophy (MSA, n=30), progressive supranuclear palsy (PSP, n=30), Alzheimer’s disease (AD, n=33), and healthy individuals (n=29), were profiled by proton NMR both at 950 MHz and on an IVDr 600 MHz system. First, we reproduced the 6M-BB performance for PD vs. HC with 87.9% accuracy, but above all, we obtained an overall accuracy of 82.6% across all groups including MSA/PSP. Secondly, the 6M-BB refit using IVDr data achieved an overall accuracy of 77%. Adding VLDL-5 free cholesterol (V5FC) and citrate markedly increased accuracy to 95% for PD vs. HC and 85% vs. MSA/PSP. To conclude, in addition to independently validate the 6M-BB with a new PD/HC cohort, we demonstrated here its ability to efficiently distinguish PD from other confounding parkinsonian syndromes at de novo stage, thereby addressing a major challenge in the early clinical diagnosis of the disease. Its successful transfer to a fully automated, standardized IVDr system, with gains from V5FC and citrate, supports the feasibility and promising potential for clinical implementation, justifying future prospective multicenter studies. One Sentence Summary: We offer a clinically deployable blood biomarker that addresses the major challenge of distinguishing Parkinson’s disease from other parkinsonism.
- Open Access
Daily intermittent fasting is an effective multiscale treatment in preclinical models of absence epilepsy
Objective: Absence epilepsy is characterized by brief but frequent seizures with loss of consciousness. Existing treatments, which come with heavy side effects, are only partially effective and do not address the associated comorbidities, including cognitive and social deficits. A tripartite link between seizures, cognitive deficits, and diet has been established. Intermittent fasting (IF) is a regime where daily periods of fasting are alternated with periods of food intake. To date, the effects of IF on infantile epilepsy have not been addressed. We evaluated the therapeutic potential of a daily, 1‐month protocol of IF on an established model of generalized absence epilepsy, the Grm7 AAA knock‐in mouse. Methods: To assess the effects of IF in mice, we combined electroencephalography, behavior analysis, high‐throughput RNA sequencing, and histology approaches. Results: We demonstrate for the first time that daily IF reduces social recognition deficits and epileptic seizures. These effects are associated with the remodeling of the cerebral vascular system. We identified a deregulation of genes involved in vascularization, reflected in the malformation of blood vessels in one of the key brain areas of the absence seizure circuit, the thalamus. Along with its antiseizure effects, we show that IF is able to counteract both abnormal gene expression and vessel morphology. Finally, we demonstrate that IF successfully reduces both seizure frequency and social interaction deficits in the AY‐9944 mouse, a preclinical model of atypical absence seizures, found in more severe epileptic syndromes. Significance: Taken together, this study is the first to demonstrate the positive and multiscale effects of IF in the treatment of absence epilepsy.
Open AccessDaily intermittent fasting is an effective multiscale treatment in preclinical models of absence epilepsy
Objective: Absence epilepsy is characterized by brief but frequent seizures with loss of consciousness. Existing treatments, which come with heavy side effects, are only partially effective and do not address the associated comorbidities, including cognitive and social deficits. A tripartite link between seizures, cognitive deficits, and diet has been established. Intermittent fasting (IF) is a regime where daily periods of fasting are alternated with periods of food intake. To date, the effects of IF on infantile epilepsy have not been addressed. We evaluated the therapeutic potential of a daily, 1‐month protocol of IF on an established model of generalized absence epilepsy, the Grm7 AAA knock‐in mouse. Methods: To assess the effects of IF in mice, we combined electroencephalography, behavior analysis, high‐throughput RNA sequencing, and histology approaches. Results: We demonstrate for the first time that daily IF reduces social recognition deficits and epileptic seizures. These effects are associated with the remodeling of the cerebral vascular system. We identified a deregulation of genes involved in vascularization, reflected in the malformation of blood vessels in one of the key brain areas of the absence seizure circuit, the thalamus. Along with its antiseizure effects, we show that IF is able to counteract both abnormal gene expression and vessel morphology. Finally, we demonstrate that IF successfully reduces both seizure frequency and social interaction deficits in the AY‐9944 mouse, a preclinical model of atypical absence seizures, found in more severe epileptic syndromes. Significance: Taken together, this study is the first to demonstrate the positive and multiscale effects of IF in the treatment of absence epilepsy.
- Open Access
- 18 May 2025
- Published by Elsevier in NeuroImage
- Vol. 315, 121274
Mapping GABA+/Glx in experimental temporal lobe epilepsy using edited-MRSI at 9.4T
- 18 May 2025
- Published by Elsevier in NeuroImage
- Vol. 315, 121274
Open AccessMapping GABA+/Glx in experimental temporal lobe epilepsy using edited-MRSI at 9.4T
- Open Access
Daily intermittent fasting is an effective multiscale treatment in preclinical models of absence epilepsy
Absence epilepsy (AE) is characterized by brief but frequent seizures with loss of consciousness. Existing treatments have heavy side effects, are only partially effective and do not address the comorbidities, including cognitive and social deficits. A tripartite link between seizures, cognitive deficits and diet has been established. We focused on intermittent fasting (IF), a regime where daily periods of fasting alternate with periods of food intake, with no restrictions in the type or quantity of food consumed. To date, the effects of IF on infantile epilepsy have not been addressed. We evaluated the therapeutic potential of a daily, one-month protocol of IF on three established mouse models of AE: the Grm7 AAA KI mouse, the Scn2a haploinsufficiency mouse and the pharmacologically-induced AY-9944 mouse model. We show a reduction of the seizure frequency in all models, as well as an improvement of the sociability deficits observed in two of the models, with no adverse effects. Focusing on the Grm7 AAA KI model, we performed RNA sequencing in a one of the key brain areas of the absence seizure circuit, the thalamus. We detected a deregulation of genes involved in vascularization associated with the development of malformed blood vessels in epileptic mice. Along with its anti-seizure effects, IF was able to counteract both abnormal gene expression and vessel morphology. This study demonstrates for the first time the positive effects of IF on AE and could facilitate the implementation of the diet in clinical trials.
Open AccessDaily intermittent fasting is an effective multiscale treatment in preclinical models of absence epilepsy
Absence epilepsy (AE) is characterized by brief but frequent seizures with loss of consciousness. Existing treatments have heavy side effects, are only partially effective and do not address the comorbidities, including cognitive and social deficits. A tripartite link between seizures, cognitive deficits and diet has been established. We focused on intermittent fasting (IF), a regime where daily periods of fasting alternate with periods of food intake, with no restrictions in the type or quantity of food consumed. To date, the effects of IF on infantile epilepsy have not been addressed. We evaluated the therapeutic potential of a daily, one-month protocol of IF on three established mouse models of AE: the Grm7 AAA KI mouse, the Scn2a haploinsufficiency mouse and the pharmacologically-induced AY-9944 mouse model. We show a reduction of the seizure frequency in all models, as well as an improvement of the sociability deficits observed in two of the models, with no adverse effects. Focusing on the Grm7 AAA KI model, we performed RNA sequencing in a one of the key brain areas of the absence seizure circuit, the thalamus. We detected a deregulation of genes involved in vascularization associated with the development of malformed blood vessels in epileptic mice. Along with its anti-seizure effects, IF was able to counteract both abnormal gene expression and vessel morphology. This study demonstrates for the first time the positive effects of IF on AE and could facilitate the implementation of the diet in clinical trials.
- 27 July 2022
- Published by Springer Nature in Molecular Neurobiology
- Vol. 59 (10) , 6170-6182
Re-routing Metabolism by the Mitochondrial Pyruvate Carrier Inhibitor MSDC-0160 Attenuates Neurodegeneration in a Rat Model of Parkinson’s Disease
A growing body of evidence supports the idea that mitochondrial dysfunction might represent a key feature of Parkinson’s disease (PD). Central regulators of energy production, mitochondria, are also involved in several other essential functions such as cell death pathways and neuroinflammation which make them a potential therapeutic target for PD management. Interestingly, recent studies related to PD have reported a neuroprotective effect of targeting mitochondrial pyruvate carrier (MPC) by the insulin sensitizer MSDC-0160. As the sole point of entry of pyruvate into the mitochondrial matrix, MPC plays a crucial role in energetic metabolism which is impacted in PD. This study therefore aimed at providing insights into the mechanisms underlying the neuroprotective effect of MSDC-0160. We investigated behavioral, cellular, and metabolic impact of chronic MSDC-0160 treatment in unilateral 6-OHDA PD rats. We evaluated mitochondrially related processes through the expression of pivotal mitochondrial enzymes in dorsal striatal biopsies and the level of metabolites in serum samples using nuclear magnetic resonance spectroscopy (NMR)–based metabolomics. MSDC-0160 treatment in unilateral 6-OHDA rats improved motor behavior, decreased dopaminergic denervation, and reduced mTOR activity and neuroinflammation. Concomitantly, MSDC-0160 administration strongly modified energy metabolism as revealed by increased ketogenesis, beta oxidation, and glutamate oxidation to satisfy energy needs and maintain energy homeostasis. MSDC-0160 exerts its neuroprotective effect through reorganization of multiple pathways connected to energy metabolism.
- 27 July 2022
- Published by Springer Nature in Molecular Neurobiology
- Vol. 59 (10) , 6170-6182
Re-routing Metabolism by the Mitochondrial Pyruvate Carrier Inhibitor MSDC-0160 Attenuates Neurodegeneration in a Rat Model of Parkinson’s Disease
A growing body of evidence supports the idea that mitochondrial dysfunction might represent a key feature of Parkinson’s disease (PD). Central regulators of energy production, mitochondria, are also involved in several other essential functions such as cell death pathways and neuroinflammation which make them a potential therapeutic target for PD management. Interestingly, recent studies related to PD have reported a neuroprotective effect of targeting mitochondrial pyruvate carrier (MPC) by the insulin sensitizer MSDC-0160. As the sole point of entry of pyruvate into the mitochondrial matrix, MPC plays a crucial role in energetic metabolism which is impacted in PD. This study therefore aimed at providing insights into the mechanisms underlying the neuroprotective effect of MSDC-0160. We investigated behavioral, cellular, and metabolic impact of chronic MSDC-0160 treatment in unilateral 6-OHDA PD rats. We evaluated mitochondrially related processes through the expression of pivotal mitochondrial enzymes in dorsal striatal biopsies and the level of metabolites in serum samples using nuclear magnetic resonance spectroscopy (NMR)–based metabolomics. MSDC-0160 treatment in unilateral 6-OHDA rats improved motor behavior, decreased dopaminergic denervation, and reduced mTOR activity and neuroinflammation. Concomitantly, MSDC-0160 administration strongly modified energy metabolism as revealed by increased ketogenesis, beta oxidation, and glutamate oxidation to satisfy energy needs and maintain energy homeostasis. MSDC-0160 exerts its neuroprotective effect through reorganization of multiple pathways connected to energy metabolism.
- Open Access
- 15 February 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (4)
A metabolic biomarker predicts Parkinson’s disease at the early stages in patients and animal models
Background. Care management of Parkinson’s disease (PD) patients currently remains symptomatic, mainly because diagnosis relying on the expression of the cardinal motor symptoms is made too late. Earlier detection of PD therefore represents a key step for developing therapies able to delay or slow down its progression. Methods. We investigated metabolic markers in 3 different animal models of PD, mimicking different phases of the disease assessed by behavioral and histological evaluation, and in 3 cohorts of de novo PD patients and matched controls (n = 129). Serum and brain tissue samples were analyzed by nuclear magnetic resonance spectroscopy and data submitted to advanced multivariate statistics. Results. Our translational strategy reveals common metabolic dysregulations in serum of the different animal models and PD patients. Some of them were mirrored in the tissue samples, possibly reflecting pathophysiological mechanisms associated with PD development. Interestingly, some metabolic dysregulations appeared before motor symptom emergence and could represent early biomarkers of PD. Finally, we built a composite biomarker with a combination of 6 metabolites. This biomarker discriminated animals mimicking PD from controls, even from the first, nonmotor signs and, very interestingly, also discriminated PD patients from healthy subjects. Conclusion. From our translational study, which included 3 animal models and 3 de novo PD patient cohorts, we propose a promising biomarker exhibiting a high accuracy for de novo PD diagnosis that may possibly predict early PD development, before motor symptoms appear. Funding. French National Research Agency (ANR), DOPALCOMP, Institut National de la Santé et de la Recherche Médicale, Université Grenoble Alpes, Association France Parkinson.
- 15 February 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (4)
Open AccessA metabolic biomarker predicts Parkinson’s disease at the early stages in patients and animal models
Background. Care management of Parkinson’s disease (PD) patients currently remains symptomatic, mainly because diagnosis relying on the expression of the cardinal motor symptoms is made too late. Earlier detection of PD therefore represents a key step for developing therapies able to delay or slow down its progression. Methods. We investigated metabolic markers in 3 different animal models of PD, mimicking different phases of the disease assessed by behavioral and histological evaluation, and in 3 cohorts of de novo PD patients and matched controls (n = 129). Serum and brain tissue samples were analyzed by nuclear magnetic resonance spectroscopy and data submitted to advanced multivariate statistics. Results. Our translational strategy reveals common metabolic dysregulations in serum of the different animal models and PD patients. Some of them were mirrored in the tissue samples, possibly reflecting pathophysiological mechanisms associated with PD development. Interestingly, some metabolic dysregulations appeared before motor symptom emergence and could represent early biomarkers of PD. Finally, we built a composite biomarker with a combination of 6 metabolites. This biomarker discriminated animals mimicking PD from controls, even from the first, nonmotor signs and, very interestingly, also discriminated PD patients from healthy subjects. Conclusion. From our translational study, which included 3 animal models and 3 de novo PD patient cohorts, we propose a promising biomarker exhibiting a high accuracy for de novo PD diagnosis that may possibly predict early PD development, before motor symptoms appear. Funding. French National Research Agency (ANR), DOPALCOMP, Institut National de la Santé et de la Recherche Médicale, Université Grenoble Alpes, Association France Parkinson.
- Open Access
- 6 January 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (1) , 156-166
The metabolic reprogramming in acute myeloid leukemia patients depends on their genotype and is a prognostic marker
Leukemic cells display some alterations in metabolic pathways, which play a role in leukemogenesis and in patients’ prognosis. To evaluate the characteristics and the impact of this metabolic reprogramming, we explore the bone marrow samples from 54 de novo acute myeloid leukemia (AML) patients, using an untargeted metabolomics approach based on proton high-resolution magic angle spinning-nuclear magnetic resonance. The spectra obtained were subjected to multivariate statistical analysis to find specific metabolome alterations and biomarkers correlated to clinical features. We found that patients display a large diversity of metabolic profiles, according to the different AML cytologic subtypes and molecular statuses. The link between metabolism and molecular status was particularly strong for the oncometabolite 2-hydroxyglutarate (2-HG), whose intracellular production is directly linked to the presence of isocitrate dehydrogenase mutations. Moreover, patients’ prognosis was strongly impacted by several metabolites, such as 2-HG that appeared as a good prognostic biomarker in our cohort. Conversely, deregulations in phospholipid metabolism had a negative impact on prognosis through 2 main metabolites (phosphocholine and phosphoethanolamine), which could be potential aggressiveness biomarkers. Finally, we highlighted an overexpression of glutathione and alanine in chemoresistant patients. Overall, our results demonstrate that different metabolic pathways could be activated in leukemic cells according to their phenotype and maturation levels. This confirms that metabolic reprogramming strongly influences prognosis of patients and underscores a particular role of certain metabolites and associated pathways in AML prognosis, suggesting common mechanisms developed by leukemic cells to maintain their aggressiveness even after well-conducted induction chemotherapy.
- 6 January 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (1) , 156-166
Open AccessThe metabolic reprogramming in acute myeloid leukemia patients depends on their genotype and is a prognostic marker
Leukemic cells display some alterations in metabolic pathways, which play a role in leukemogenesis and in patients’ prognosis. To evaluate the characteristics and the impact of this metabolic reprogramming, we explore the bone marrow samples from 54 de novo acute myeloid leukemia (AML) patients, using an untargeted metabolomics approach based on proton high-resolution magic angle spinning-nuclear magnetic resonance. The spectra obtained were subjected to multivariate statistical analysis to find specific metabolome alterations and biomarkers correlated to clinical features. We found that patients display a large diversity of metabolic profiles, according to the different AML cytologic subtypes and molecular statuses. The link between metabolism and molecular status was particularly strong for the oncometabolite 2-hydroxyglutarate (2-HG), whose intracellular production is directly linked to the presence of isocitrate dehydrogenase mutations. Moreover, patients’ prognosis was strongly impacted by several metabolites, such as 2-HG that appeared as a good prognostic biomarker in our cohort. Conversely, deregulations in phospholipid metabolism had a negative impact on prognosis through 2 main metabolites (phosphocholine and phosphoethanolamine), which could be potential aggressiveness biomarkers. Finally, we highlighted an overexpression of glutathione and alanine in chemoresistant patients. Overall, our results demonstrate that different metabolic pathways could be activated in leukemic cells according to their phenotype and maturation levels. This confirms that metabolic reprogramming strongly influences prognosis of patients and underscores a particular role of certain metabolites and associated pathways in AML prognosis, suggesting common mechanisms developed by leukemic cells to maintain their aggressiveness even after well-conducted induction chemotherapy.
In vivo γ‐aminobutyric acid increase as a biomarker of the epileptogenic zone: An unbiased metabolomics approach
Objective: Following surgery, focal seizures relapse in 20% to 50% of cases due to the difficulty of delimiting the epileptogenic zone (EZ) by current imaging or electrophysiological techniques. Here, we evaluate an unbiased metabolomics approach based on ex vivo and in vivo nuclear magnetic resonance spectroscopy (MRS) methods to discriminate the EZ in a mouse model of mesiotemporal lobe epilepsy (MTLE).Methods: Four weeks after unilateral injection of kainic acid (KA) into the dorsal hippocampus of mice (KA‐MTLE model), we analyzed hippocampal and cortical samples with high‐resolution magic angle spinning (HRMAS) magnetic resonance spectroscopy (MRS). Using advanced multivariate statistics, we identified the metabolites that best discriminate the injected dorsal hippocampus (EZ) and developed an in vivo MEGAPRESS MRS method to focus on the detection of these metabolites in the same mouse model.Results: Multivariate analysis of HRMAS data provided evidence that γ‐aminobutyric acid (GABA) is largely increased in the EZ of KA‐MTLE mice and is the metabolite that best discriminates the EZ when compared to sham and, more importantly, when compared to adjacent brain regions. These results were confirmed by capillary electrophoresis analysis and were not reversed by a chronic exposition to an antiepileptic drug (carbamazepine). Then, using in vivo noninvasive GABA‐edited MRS, we confirmed that a high GABA increase is specific to the injected hippocampus of KA‐MTLE mice.Significance: Our strategy using ex vivo MRS‐based untargeted metabolomics to select the most discriminant metabolite(s), followed by in vivo MRS‐based targeted metabolomics, is an unbiased approach to accurately define the EZ in a mouse model of focal epilepsy. Results suggest that GABA is a specific biomarker of the EZ in MTLE.
In vivo γ‐aminobutyric acid increase as a biomarker of the epileptogenic zone: An unbiased metabolomics approach
Objective: Following surgery, focal seizures relapse in 20% to 50% of cases due to the difficulty of delimiting the epileptogenic zone (EZ) by current imaging or electrophysiological techniques. Here, we evaluate an unbiased metabolomics approach based on ex vivo and in vivo nuclear magnetic resonance spectroscopy (MRS) methods to discriminate the EZ in a mouse model of mesiotemporal lobe epilepsy (MTLE).Methods: Four weeks after unilateral injection of kainic acid (KA) into the dorsal hippocampus of mice (KA‐MTLE model), we analyzed hippocampal and cortical samples with high‐resolution magic angle spinning (HRMAS) magnetic resonance spectroscopy (MRS). Using advanced multivariate statistics, we identified the metabolites that best discriminate the injected dorsal hippocampus (EZ) and developed an in vivo MEGAPRESS MRS method to focus on the detection of these metabolites in the same mouse model.Results: Multivariate analysis of HRMAS data provided evidence that γ‐aminobutyric acid (GABA) is largely increased in the EZ of KA‐MTLE mice and is the metabolite that best discriminates the EZ when compared to sham and, more importantly, when compared to adjacent brain regions. These results were confirmed by capillary electrophoresis analysis and were not reversed by a chronic exposition to an antiepileptic drug (carbamazepine). Then, using in vivo noninvasive GABA‐edited MRS, we confirmed that a high GABA increase is specific to the injected hippocampus of KA‐MTLE mice.Significance: Our strategy using ex vivo MRS‐based untargeted metabolomics to select the most discriminant metabolite(s), followed by in vivo MRS‐based targeted metabolomics, is an unbiased approach to accurately define the EZ in a mouse model of focal epilepsy. Results suggest that GABA is a specific biomarker of the EZ in MTLE.
- 1 July 2016
- Published by Elsevier in Environmental Pollution
- Vol. 214, 539-548
Effect of organochlorine pesticides exposure on the maize root metabolome assessed using high-resolution magic-angle spinning 1H NMR spectroscopy
- 1 July 2016
- Published by Elsevier in Environmental Pollution
- Vol. 214, 539-548
Effect of organochlorine pesticides exposure on the maize root metabolome assessed using high-resolution magic-angle spinning 1H NMR spectroscopy
- 5 August 2015
- Published by Springer Nature in Metabolomics
- Vol. 11 (6) , 1834-1847
The three glioma rat models C6, F98 and RG2 exhibit different metabolic profiles: in vivo 1H MRS and ex vivo 1H HRMAS combined with multivariate statistics
- 5 August 2015
- Published by Springer Nature in Metabolomics
- Vol. 11 (6) , 1834-1847
The three glioma rat models C6, F98 and RG2 exhibit different metabolic profiles: in vivo 1H MRS and ex vivo 1H HRMAS combined with multivariate statistics